Renalytix Plc (RNLXY) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · OTC
Renalytix Plc (RNLXY) stock forecast summary
Our AI scores Renalytix Plc every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Its market capitalization is not available, so no size classification is given.
For RNLXY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -15.0%, measured on 342 forecast dates between 2022-12-02 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 1.0%, measured on 385 forecast dates between 2022-12-02 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, RNLXY included.
RNLXY price chart and AI forecast
How RNLXY ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Renalytix Plc (RNLXY) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.
Valuation & Market
| Metric | RNLXY | Rank |
|---|---|---|
| EPS | $-0.12 | – |
Profitability & Margins
| Metric | RNLXY | Rank |
|---|---|---|
| ROA | -520.3% | 17/18 |
| Gross Margin | 10.4% | 13/15 |
| Operating Margin | -1332.8% | 19/21 |
| Net Margin | -1179.8% | 15/16 |
| EBT Margin | -1471.3% | 19/21 |
| Tax Rate | -0.0% | – |
Financial Health
| Metric | RNLXY | Rank |
|---|---|---|
| Interest Coverage | -26.3x | 14/21 |
Cash Flow
| Metric | RNLXY | Rank |
|---|---|---|
| Operating Cash Flow | -$26M | 20/25 |
Income Statement
| Metric | RNLXY | Rank |
|---|---|---|
| Operating Income | -$28M | 17/24 |
| Net Income | -$25M | 11/19 |
| R&D Expense | $9M | 14/18 |
| Cost of Goods Sold | $2M | 12/14 |
Balance Sheet Highlights (USD millions)
| Total Liabilities | $16M |
RNLXY quarterly financials and insider trading
Renalytix Plc (RNLXY) industry peers
Companies classified under the same SEC industry code as Renalytix Plc (Services-Medical Laboratories): 28 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| RNLXY Renalytix Plc | N/A | |
| NTRA Natera, Inc. | $44.78B | |
| LH Labcorp Holdings Inc. | $29.77B | |
| DGX Quest Diagnostics Inc | $28.12B | |
| GH Guardant Health, Inc. | $20.25B | |
| CAI Caris Life Sciences, Inc. | $7.13B | |
| RDNT Radnet, Inc. | $5.98B | |
| GRAL Grail, Inc. | $5.42B | |
| BLLN Billiontoone, Inc. | $5.38B | |
| CDNA Caredx, Inc. | $4.13B | |
| CELC Celcuity Inc. | $3.27B | |
| FTRE Fortrea Holdings Inc. | $2.12B | |
| VCYT Veracyte, Inc. | $1.94B | |
| PSNL Personalis, Inc. | $1.69B | |
| LMRI Lumexa Imaging Holdings, Inc. | $1.29B | |
| FRNM Freenome, Inc. | $1.09B | |
| CSTL Castle Biosciences Inc | $993M | |
| FLGT Fulgent Genetics, Inc. | $653M | |
| XGN Exagen Inc. | $184M | |
| BNR Burning Rock Biotech Ltd | $143M | |
| BDSX Biodesix Inc | $90M | |
| SERA Sera Prognostics, Inc. | $82M | |
| MDXH Mdxhealth Sa | $14M | |
| AMS American Shared Hospital Services | $8M | |
| ACON Aclarion, Inc. | $4M | |
| ADVB Advanced Biomed Inc. | $3M | |
| BGLC Bionexus Gene Lab Corp | $3M | |
| FCHS First Choice Healthcare Solutions, Inc. | $150K |
Where RNLXY sits on the market map
Renalytix Plc (RNLXY) stock news
Loading...
Renalytix Plc (RNLXY) stock forecast FAQ
What is the Renalytix Plc (RNLXY) stock forecast?
Our AI scores Renalytix Plc every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Renalytix Plc stock predictions?
For RNLXY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -15.0%, measured on 342 forecast dates between 2022-12-02 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 1.0%, measured on 385 forecast dates between 2022-12-02 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Renalytix Plc forecasts updated?
Renalytix Plc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Renalytix Plc's industry peers?
28 issuers in our coverage, RNLXY included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Labcorp Holdings Inc. (LH), Quest Diagnostics Inc (DGX), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Radnet, Inc. (RDNT).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.